Dali Pharmaceuticalco.Ltd Management
Management criteria checks 4/4
Dali Pharmaceuticalco.Ltd's CEO is Jun Xiang Yang, appointed in Oct 2021, has a tenure of 3.17 years. directly owns 23.31% of the company’s shares, worth CN¥133.64M. The average tenure of the management team and the board of directors is 5.7 years and 10.4 years respectively.
Key information
Jun Xiang Yang
Chief executive officer
CN¥583.3k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3.2yrs |
| CEO ownership | 23.3% |
| Management average tenure | 5.7yrs |
| Board average tenure | 10.4yrs |
CEO
Jun Xiang Yang (62 yo)
3.2yrs
Tenure
CN¥583,300
Compensation
Mr. Jun Xiang Yang has been General Manager at Dali Pharmaceutical Co., Ltd since October 12, 2021. Mr. Yang serves as Executive director and general manager at Dali Junkang Investment Co., Ltd. He has bee...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & GM | 3.2yrs | CN¥583.30k | 23.31% CN¥ 140.8m | |
| Deputy GM | 16.8yrs | CN¥347.70k | no data | |
| Assistant GM | no data | CN¥236.50k | 0.56% CN¥ 3.4m | |
| Board Secretary | 5.7yrs | CN¥236.50k | 0.0046% CN¥ 27.5k |
5.7yrs
Average Tenure
57yo
Average Age
Experienced Management: 603963's management team is seasoned and experienced (5.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & GM | 16.8yrs | CN¥583.30k | 23.31% CN¥ 140.8m | |
| Assistant GM | 16.8yrs | CN¥236.50k | 0.56% CN¥ 3.4m | |
| Vice Chairman | 4.4yrs | CN¥400.00k | 3.06% CN¥ 18.5m | |
| Director | 4.4yrs | CN¥160.00k | no data | |
| Vice Chairman of the Board | 10.4yrs | CN¥240.00k | no data | |
| Director | 9.5yrs | CN¥80.00k | no data | |
| Chairman of the Supervisory Board | 10.4yrs | no data | no data | |
| Member of the Supervisory Board | 10.4yrs | no data | no data |
10.4yrs
Average Tenure
58.5yo
Average Age
Experienced Board: 603963's board of directors are seasoned and experienced ( 10.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 16:38 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dali Pharmaceuticalco.,Ltd is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jiaxi Xu | Industrial Securities Co. Ltd. |